# Interventions to Support People With HIV Following Hospital Discharge: A Systematic Review

Nathan Ford,<sup>1,2,®</sup> Ajay Rangaraj,<sup>1</sup> Joseph N. Jarvis,<sup>3,4</sup> David S. Lawrence,<sup>3,4,5,®</sup> Roger Chou,<sup>6</sup> Alena Kamenshchikova,<sup>7,8,9,®</sup> Sally Hargreaves,<sup>10</sup> and Rachael M. Burke<sup>3,11</sup>

<sup>1</sup>Department of HIV, Viral Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland, <sup>2</sup>Centre for Integrated Data and Epidemiological Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, <sup>3</sup>Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK, <sup>4</sup>Botswana Harvard Health Partnership, Gaborone, Botswana, <sup>5</sup>School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, <sup>6</sup>Pacific Northwest Evidence-Based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA, <sup>7</sup>Department of Health, Ethics and Society, Maastricht University, Maastricht, Netherlands, <sup>8</sup>Department of Social Medicine, Maastricht University, Maastricht University, Maastricht University, Maastricht, Netherlands, <sup>10</sup>Institute for Infection and Immunity, City St George's University of London, London, UK, and <sup>11</sup>Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi

**Background.** Individuals hospitalized with HIV-related complications face high post-discharge mortality and morbidity, particularly in resource-limited settings. This systematic review evaluated the impact of interventions to reduce post-hospital mortality, lower readmissions, and improve linkage to care.

*Methods.* We searched the PubMed, Embase, and Cochrane databases up to 1 October 2024 for studies reporting outcomes of post-discharge interventions. Two independent reviewers performed study selection, extracted data, and assessed risk of bias. We pooled data using random effects meta-analysis.

**Results.** We included 4 randomized controlled trials (conducted in Spain, South Africa, Tanzania, and the United States) and 6 observational studies (Canada, Thailand, Zambia, and the United States). Interventions included pre-discharge counseling, medication review, referral to care, and goal setting, as well as post-discharge follow-up via home visits, telephone calls, and support from social workers or community health workers. Pooled data from randomized controlled trials showed no difference between post-discharge interventions and usual care in mortality, but the estimate was imprecise (relative risk [RR], 0.98; 95% CI, .59–1.63). However, interventions may reduce readmissions (RR, 0.82; 95% CI, .52–1.30) and may slightly improve linkage/ retention in care (RR, 1.10; 95% CI, .95–1.27). Observational studies reported similar results, with no mortality effect but potential reductions in readmissions (RR, 0.77; 95% CI, .48–1.25) and improved linkage/retention (RR, 1.42; 95% CI, 1.11–1.81). Interventions were largely feasible, acceptable, and low cost.

**Conclusions.** Interventions that include pre-discharge care planning and post-discharge follow-up, such as telephone contact and home visits, may improve linkage to care and reduce readmissions. However, interventions were not associated with reduced post-discharge mortality.

Keywords. discharge; HIV; hospitalization; mortality; readmission.

Despite improved access to antiretroviral therapy, hospitalizations from complications relating to HIV infection, including coinfections associated with advanced HIV disease, remain

#### **Open Forum Infectious Diseases**<sup>®</sup>

substantial [1–3]. People who are hospitalized with HIV-related illness are at high risk of death [4–7], and this risk persists after discharge from inpatient care. A systematic review published in 2022 found that 19% of people with HIV were subsequently readmitted to hospital after discharge and 14% had died [2]. In a prospective cohort study from Tanzania published in 2016, almost a third of deaths occurred within 3 months after hospital discharge [8].

Several studies have identified factors associated with poor post-discharge outcomes, such as readmission, failed linkage to care, and death among people with HIV. These risk factors include low CD4 cell count [9], not taking antiretroviral therapy at admission or discharge [10], and discharge against medical advice [11]. Poor functional status (ie, inability to perform normal daily activities) is also an important predictor of mortality [1].

Individuals with HIV who are admitted to a hospital should be considered at high risk for death in the following 12 months [12], and there is a need to identify effective ways to reduce post-

Received 24 January 2025; editorial decision 14 March 2025; accepted 18 March 2025; published online 20 March 2025

Correspondence: Nathan Ford, DSc, Department of HIV, Viral Hepatitis and Sexually Transmitted Infections, World Health Organization, Geneva, Switzerland (fordn@who.int); Rachael Burke, PhD, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK (rachael.burke@ Ishtm.ac.uk).

<sup>©</sup> The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. https://doi.org/10.1093/ofid/ofaf175

hospital mortality. We conducted this systematic review to summarize the available evidence on interventions to improve clinical outcomes after hospitalization among people with HIV.

## METHODS

This systematic review and meta-analysis adhered to the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-analyses). The study protocol is available in the supplementary appendix.

Using a highly sensitive search strategy developed by an information specialist, we searched PubMed, Embase, and the Cochrane library from inception to 1 October 2024 for studies assessing interventions to improve outcomes following hospital discharge. Abstracts from IAS and CROI were screened from 2022 to 2024 to identify studies not yet published in full, as were the bibliographies of included articles. Randomized trials and comparative observational studies were included if they reported on the impact of an intervention on the following outcomes among people with HIV: post-discharge mortality, readmission, or linkage/retention after hospital care; linkage and retention were combined, as both terms refer to follow-up care in outpatient services in the early post-discharge period. There were no restrictions based on follow-up time. Information on cost and acceptability was extracted if reported. Study selection and data extraction were conducted by at least 2 reviewers working independently and in pairs (N. F., A. K., A. R.), with any disagreements resolved by consensus. Summary extraction tables were shared with study investigators for verification.

We extracted data on population, details of the intervention and comparator, and outcomes (including the number of patients who died, were readmitted to care, and were successfully linked to community health care services). We assessed risk of bias using the Cochrane tool for randomized trials and an adapted Newcastle Ottawa scale for observational studies, and this assessment was used to inform a GRADE assessment of evidence certainty [13]. We calculated relative risks (RRs) and corresponding 95% CIs for each outcome and pooled the data using random effects meta-analysis because of anticipated heterogeneity. Outcomes were pooled separately for randomized trials and observational studies. For observational studies, we used raw (unadjusted) data, with studies weighted by within- and between-study variance to account for heterogeneity across studies. A post hoc decision was taken to pool outcomes across study designs as a supplemental analysis, given the limited data and considering the similarities between follow-up of studies with and without baseline randomization for these interventions [14]. All analyses were carried out in Stata version 15 (StataCorp).

# RESULTS

From an initial screen of 2305 abstracts, 10 studies consisting of 3202 participants were included in the analysis (Figure 1). Four studies were randomized trials conducted in Spain [15], South Africa [12], Tanzania [16], and the United States [17]. Six studies were observational designs: a prospective single-arm study from Canada [18], pre- and post-analysis studies from Thailand and the United States [19, 20], an interrupted time series from the United States [21], a retrospective study from the United States [22], and a quasi-experimental study from Zambia [23] (Table 1). Where cause of admission was reported, HIV-related causes were common [12, 22]; at admission, the proportion of patients with advanced HIV disease (defined as CD4 <200 cells/ mm<sup>3</sup>) ranged from 31% to 66% [12, 15-18, 20, 21]. All studies were conducted among adults, including patients with severe [12, 15–19, 21] to moderate [20, 22] immunosuppression. Four studies were in select populations at higher risk of poor outcomes (eg, people not in antiretroviral therapy care) [15-18], and 6 recruited a general group of hospitalized people with HIV.

All interventions evaluated had pre- and post-discharge components. Pre-discharge interventions refer to those offered during hospital admission, and post-discharge interventions refer to those offered at a variable period following discharge from hospital (immediately to several months after discharge). Pre-discharge interventions included counseling (3 studies [16, 17, 22]), care referral (3 studies [12, 19, 21]), medication review (2 studies [20, 22]), goal setting (1 study [18]), and follow-up instructions (2 studies [19, 23]). Post-discharge interventions consisted of home visits (4 studies) conducted by nurses [12] or social support/community health workers [12, 16, 22, 23] and telephone follow-up, including SMS/text (7 studies [12, 15-20]). Support was provided by social workers [16, 22], peer volunteers [18], or patient care navigators [22]; 2 studies employed pharmacists to support medication follow-up (Table 1, Supplementary Appendix) [15, 20]. Mortality within 30 days was cited by 1 study [19]; the rest reported mortality at 6 to 12 months [12, 16, 17, 23]. Four studies assessed readmission within 30 days [19, 20, 22]-a common metric for assessing quality care-while the rest reported readmission 6 to 12 months after discharge. The follow-up time for assessing linkage/retention in care varied from 30 days [17, 19, 22] to 12 months [16]. Six studies provided less intensive discharge support to participants in the control group [12, 15, 16, 19, 22, 23].

Across the randomized trials, there was no clear evidence of a difference in mortality comparing those who did and did not receive an intervention (RR, 0.98; 95% CI, .59–1.63);  $I^2 = 46.0\%$ ): this estimate is imprecise and there were few deaths, with pooled risk differences across the trials ranging from 7 fewer to 6 more per 100 patients.



Figure 1. Study selection process.

The interventions might be associated with reduced likelihood of readmissions (RR, 0.82; 95% CI, .52–1.30;  $I^2 = 53.7\%$ ) and a slight increase in the likelihood of linkage/retention (RR, 1.10; 95% CI, .95–1.27;  $I^2 = 41\%$ ), although the confidence interval is wide, including no effect (Figure 2).

Outcomes were similar across the observational studies, which reported no difference in mortality (RR, 1.0; 95% CI, .63–1.59;  $I^2 = 0.0\%$ ), possibly decreased likelihood of readmissions (RR, 0.77; 95% CI, .48–1.25;  $I^2 = 49.0\%$ ), and increased likelihood of linkage/retention in care (RR, 1.42; 95% CI, 1.11–1.81;  $I^2 = 79.0\%$ ).

Pooling all data across study designs gave similar results: no difference in mortality (RR, 1.02; 95% CI, .79–1.32;  $I^2 = 0\%$ ) and a possible reduction in readmissions (RR, 0.87; 95% CI, .69–1.09;  $I^2 = 44.5\%$ ). There was an increase in linkage/retention in care (RR, 1.24; 95% CI, 1.07–1.44:  $I^2 = 74.0\%$ ), which translated into 18 more patients out of every 100 (6–30 patients) being linked/retained. The certainty of the evidence

was low, with downgrading mainly due to risk of bias and imprecision (supplementary appendix).

Four studies that assessed post-discharge follow-up by telephone or home visit reported that the interventions were feasible [12, 18, 23] and acceptable [15, 23]. One study that assessed social worker hospital and home care in Tanzania cited the cost of delivering the intervention at US \$22 per patient [16]. A study from Thailand stated that the intervention (enhanced inpatient rounds and telephone follow-up) was cost neutral [19]; a study from the United States found that the intervention (telephone follow-up) was cost saving through reduced readmissions [20].

# DISCUSSION

This systematic review summarizes the available evidence on interventions to improve outcomes of patients with HIV following hospital discharge. The review found a limited number

Characteristics	
Study	
le 1.	
Tabl	

						ul	tervention	
Study	Country and Year	Design	Cause of Admission	CD4	Sample Size (Intervention), Age, and Inclusion Criteria	Pre-discharge	Post-discharge	Control
Giordano [17]	USA, 2010–2013	Randomized controlled trial	Any	66% <200	417 (225); >50% >40 y; people newly diagnosed with HIV or out of care	2 in-person sessions from a peer supporter	Peer support: 5 postdischarge telephone calls; brochures	Counseling on avoiding HIV transmission
Guzman Ramos [15]	Spain, 2017–2018	Randomized controlled trial	Any	45% <200	39 (20); mean age 54.5 y; PVVH determined to be at high risk of readmission	Risk stratification for readmission	2 pharmacotherapeutic follow-up visits, motivational interviewing, information leaflets on adherence, and SMS/text	Standard care, including pharmacotherapeutic follow-up
Hoffmann [12]	South Africa, 2020– 2021	Randomized controlled trial	Medical ward (nonsurgical, obstetric, or psychiatric); TB (28%) was the leading diagnosis	49% <200	111 (63); median, 41 y; most hospitalized PWH admitted >2 d eligible	Care referrals	Telephone or home visit package with up to 6 home visits with nurse and counsellor. Macronutrient supplement for participants meeting food insecurity criteria	Instructions from discharge counselors given pre- discharge (no study-delivered postdischarge follow-up)
Peck [16]	Tanzania, 2019–2022	Randomized controlled trial	Any; 62% for infectious causes	48% <200	500 (250): mean 37 y; adults newly diagnosed with HIV or not taking ART	Intervention: first counseling session	Intervention: up to 5 sessions conducted by a social worker at hospital, home, and HIV clinic over a 3-mo period.	30-min counseling session and nurses escort to HIV clinic for appointment schedule
Brizzi [20]	USA, 2017–2018	Pre- and post- analysis	Any	31% <200	128 (68); median 47 y; adults who were being followed up at outpatient clinic in same hospital	Review of medications	Pharmacist-driven ART stewardship; transitions of care service; telephone follow-up within 7 d for high-risk patients	Standard care
Claassen [23]	Zambia, 2023	Quasi-experimental study	Any	÷	224 (100); median 41 y; all adult hospitalized PWH	Discharge card: diagnoses, laboratory tests, medications, follow-up instructions	Community health worker visit within 7 d of discharge to check vital signs, adherence, counseling, and referral as needed. Additional visits up to 3 mo	Standard care with telephone follow-up
Eaton [18]	Canada, 2017–2018	Prospective observational study	ART (re)initiation; substance use	36% <200	17 (17); mean 49 y; adults admitted to a specialist hospital for subacute and respite HIV care; drug use common among participants	Goal setting with nurse; meeting with peer volunteer	9 phone calls with peer volunteer over 7 wk	Pone
Hill [22]	USA, 2020-2021	Retrospective observational study <sup>b</sup>	Any; 40% had AIDS-defining illness at admission	Mediam CD4 223	114 (77); median 51 y; all hospitalized adults who were scheduled for a discharge clinic visit	Medication counseling	Patient care navigators provide appointment reminders and assist with transport to	Standard care, including medication counseling

						Int	ervention	
Study	Country and Year	Design	Cause of Admission	CD4	Sample Size (Intervention), Age, and Inclusion Criteria	Pre-discharge	Post-discharge	Control
							discharge clinic; doctor, social workers, and counselors address psychosocial needs; and pharmacists assist with medication reconciliation at discharge clinic.	
Khawcharoenporm <sup>a</sup> [19]	- Thailand, 2014-2015	Pre- and postanalysis	Any	Mediam CD4 158	240 (120); median 37 y; all hospitalized adult PWH	Enhanced inpatient rounds, including a social worker and peer supporter and instructions about how to make a follow-up appointment	Appointment reminders, patient education, and telephone calls. Written materials	Standard care, including instructions on how to make a follow-up appointment
Nijhawan [21]	USA, 2012-2016	Interrupted time series	Any	33% <200	1412 (1103); median 43 <i>y;</i> all hospitalized adult PWH	Review barriers to care, complete patient education, and develop an individualized transitional care plan; multidisciplinary transition team	Medical HIV consultation ± transitional care nurse intervention	Standard care (no case management)
Abbreviations: ART, ar <sup>a</sup> Intervention participal <sup>b</sup> Ctudied people who o	ntiretroviral therapy; PWH, pé nts (where disaggregated). Vid and did not attend a disch	eople with HIV; TB, tuberculo	sis. to olinio)					
ornared beckie with r	יום פוום חום ווחר פונכוום פ מוסמי.	Iai ye ullilu (ali peopie iliviteu						

Table 1. Continued

Study	Relative risk (95% Cl)	Risk difference per 100 people (95% Cl)
Deaths		
Randomized trials		
Hoffman	0.41 (0.14, 1.22)	11 fewer (23 fewer to 2 more)
Giordano	1.42 (0.75, 2.69)	3 more (2 fewer to 8 more)
Peck	1.02 (0.69, 1.51)	0 (6 fewer to 7 more)
Subtotal	> 0.98 (0.59, 1.63)	0 (7 fewer to 6 more)
Observational studies		
Khwcharoenporn	1.08 (0.48, 2.47)	1 more (6 fewer to 7 more)
Claasen —	0.97 (0.56, 1.70)	1 fewer (11 fewer to 10 more)
Subtotal	> 1.00 (0.63, 1.59)	0 (5 fewer to 6 more)
Overall	> 1.02 (0.79, 1.32)	0 (3 fewer to 4 more)
Readmissions		
Randomized trials		
Guzman Ramos	0.32 (0.11, 0.97)	45 fewer (83 fewer to 8 more)
Hoffman	0.79 (0.52, 1.21)	11 fewer (31 fewer to 9 more)
Giordano -+-	_ 1.09 (0.87, 1.37)	4 fewer (6 fewer to 13 fewer)
Subtotal	0.82 (0.52, 1.30)	11 fewer (33 fewer to 11 more)
Observational studies		
Khwcharoenporn	1.23 (0.34, 4.49)	1 more (3 fewer to 5 more)
Brizzi	0.44 (0.20, 0.96)	15 fewer (28 fewer to 1 more)
Nijhawan	1.01 (0.88, 1.16)	0 (2 fewer to 2 more)
Hill	_ 0.55 (0.22, 1.40)	9 fewer (23 fewer to 6 more)
Subtotal	0.77 (0.48, 1.25)	1 fewer (6 fewer to 3 more)
Overall	0.87 (0.69, 1.09)	2 fewer (7 fewer to 2 more)
Linkage/retention		
Randomized trials		
Peck +	. 1.14 (1.04, 1.25)	11 more (4 more to 18 more)
Giordano	0.99 (0.78, 1.25)	0 (10 fewer to 9 more)
Subtotal	<b>1.10 (0.95, 1.27)</b>	6 more (6 fewer to 17 more)
Observational studies		
Khwcharoenporn .	▲ 1.37 (1.21, 1.56)	26 more (17 more to 35 more)
Brizzi	_ 1.19 (1.02, 1.38)	14 more (2 more to 27 more)
Hill	2.25 (1.43, 3.55)	44 more (26 more to 62 more)
Subtotal <	1.42 (1.11, 1.81)	27 more (13 more to 41 more)
Overall	> 1.24 (1.07, 1.44)	18 more (6 more to 30 more)
I 	Г 5	
Control	Intervention	



of studies, mostly with small numbers of participants. Studies tested a number of interventions that were provided prior to and following discharge. The studies in this review provide further evidence of poor outcomes following hospital discharge, in particular post-discharge mortality, as well as some direction for interventions that can reduce readmission and improve linkage to ongoing post-discharge care. Approaches that supported improved outcomes included the provision of information and referral for follow-up care prior to discharge and follow-up through telephone communication or home visits in the weeks following discharge. Where reported, interventions were considered feasible, acceptable, and affordable.

However, there was a consistent lack of an effect on mortality, which was similarly high across intervention and control arms, ranging from 7% to 18%. Studies have mainly focused on providing psychosocial and pharmacy support, and more research is needed to assess interventions designed to improve post-discharge survival. In particular, studies are needed to identify biomedical interventions prior to and following discharge to manage opportunistic infections that were not diagnosed or fully treated during admission and to prevent, diagnose, and treat emergent infections and treatment-related toxicities. Several studies in this review reported that a substantial number of patients died in hospital prior to receiving the intervention [12, 18, 23], highlighting the need to more effectively respond to predischarge mortality [24].

Preventing unnecessary readmissions can enhance care quality and lower costs. Thirty-day readmissions are frequently used as a key indicator of health care quality, as they may indicate poor inpatient care and have a significant impact on patients' quality of life [25]. However, this outcome requires careful interpretation because readmissions may be necessary for some patients. One of the studies in this review deployed community health workers to visit the homes of patients after discharge [23], and this study reported higher readmissions in the intervention group because the intervention identified people who were not recovering well (based on vital signs). Readmissions from this study were therefore not included in the pooled estimates for this review; if this study is included in the analysis, results remain nonsignficiant (RR, 0.92; 95% CI, .65–1.30).

While most of the studies (6 studies, 66% of all participants) were conducted in high-income settings, the majority of the randomized evidence (2 trials, 57% of randomized participants) came from southern or eastern Africa. The interventions that were evaluated could be implemented in low-income settings, and where information on resources was provided, the cost of delivering the interventions was modest. The claim of cost saving through reduced readmissions reported by 1 study would apply to any intervention that reduced avoidable readmissions [20]. However, some studies engaged a number of specialized clinic staff in discharge preparation and follow-up, and that type of intervention may not be feasible in low-income hospital settings.

The certainty of the available evidence was low due to concerns regarding the randomization process and outcome measures, the confounding in the observational studies, and the small sample sizes and event rates leading to imprecise estimates. The available evidence base overall was small, comprising 4 trials and 6 observational studies, preventing the conduct of meaningful stratified analyses to explore important differences among studies that may influence outcomes such as setting, study quality, and differences in intervention components. While interventions varied, most studies provided some preparatory support in hospital and post-discharge follow-up. Outcomes across all studies lacked precision, with most individual study and pooled estimates crossing the null, including benefit and no benefit. This is largely explained by the fact that the total sample size is not large and the number of events is small, with only subsets of studies contributing data for each outcome. This is reflected in the GRADE assessment, which rated the certainty of the evidence as low, with serious risk of imprecision [26]. This highlights the need for larger studies, ideally randomized in design, with adequately powered sample sizes and sufficient follow-up.

Another limitation of the available evidence is the lack of studies conducted among children, which is an important gap given the known high mortality, particularly in resourcelimited settings [27]. There is a need for adequately powered randomized studies across all age groups. There was also limited information on feasibility, acceptability, quality of life and other patient-reported outcomes, and cost, which are important considerations for the adoption of interventions into policy and practice. Finally, we cannot exclude publication bias. While there were too few studies reporting the same outcomes to be able to assess this statistically, the strength of the available evidence does not suggest that available results differ systematically from results that may not have been published [28].

Systematic reviews of discharge interventions for patients hospitalized with heart failure [29], those with chronic obstructive pulmonary disease [30], and older patients who were chronically ill [31] have reported that transitional care interventions that bridge the care gap from hospital to home have reduced hospital readmissions, with some benefit on other health outcomes including mortality. Such indirect evidence from comparable health conditions should be considered when seeking to improve the outcomes of people with HIV following discharge from hospital.

In conclusion, the studies summarized by this review provide evidence around the effectiveness of feasible and low-cost interventions to improve linkage to care and potentially reduce readmissions but did not ultimately identify any interventions that reduce mortality.

### **Supplementary Data**

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

#### Notes

Acknowledgments. Thanks to Melissa Badowski, Cassidy Claassen, Andrew Eaton, Thomas Giordano, Lucas Hill, Christopher Hoffmann, Thana Khawcharoenporn, Anik Nijhawan, Robert Peck, and Michael Vinikoor for verifying data extractions and providing additional data. Thanks also to Shihab S. Joi for assistance with the figures.

*Author contributions.* N. F. conceived the study. N. F., A. R., and A. K. ran the search and extracted and verified the data. N. F. conducted the statistical analysis. N. F. wrote the first draft, and all authors contributed to revisions and approved the final manuscript. All authors had full access

to the data in the study and had final responsibility for the decision for submit for publication.

*Financial support.* This work was supported by the Bill and Melinda Gates Foundation through a grant to the World Health Organization.

**Potential conflicts of interest.** R. M. B., D. S. L., and J. N. J. all receive funding from the UK National Institute of Health Research to their institutions. J. N. J. and D. S. L. have also received funding from the US Centers for Disease Control and Prevention to their institutions. D. S. L. has received salary support from Janssen to his institution. R. H. B. has received support from the National Institutes of Health. J. N. J. has served on a data and safety monitoring board for 3 trials related to hospitalized people with HIV (Harvest, ARTIST, ASTRO).

#### References

- Owachi D, Akatukunda P, Nanyanzi DS, et al. Mortality and associated factors among people living with HIV admitted at a tertiary-care hospital in Uganda: a cross-sectional study. BMC Infect Dis 2024; 24:239.
- Ford N, Patten G, Rangaraj A, Davies MA, Meintjes G, Ellman T. Outcomes of people living with HIV after hospital discharge: a systematic review and metaanalysis. Lancet HIV 2022; 9:e150–9.
- Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2015; 2:e438–44.
- Akinkuotu A, Roemer E, Richardson A, et al. In-hospital mortality rates and HIV: a medical ward review, Lilongwe, Malawi. Int J STD AIDS 2011; 22:465–70.
- Wajanga BM, Webster LE, Peck RN, et al. Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review. BMC Health Serv Res 2014; 14:627.
- Hoffmann CJ, Milovanovic M, Cichowitz C, Kinghorn A, Martinson NA, Variava E. Readmission and death following hospitalization among people with HIV in South Africa. PLoS One 2019; 14:e0218902.
- Laher AE, Paruk F, Venter W, Ayeni OA, Richards GA. Predictors of in-hospital mortality among HIV-positive patients presenting with an acute illness to the emergency department. HIV Med 2021; 22:557–66.
- Peck RN, Wang RJ, Mtui G, et al. Linkage to primary care and survival after hospital discharge for HIV-infected adults in Tanzania: a prospective cohort study. J Acquir Immune Defic Syndr 2016; 73:522–30.
- Davy-Mendez T, Napravnik S, Wohl DA, et al. Hospitalization rates and outcomes among persons living with human immunodeficiency virus in the southeastern United States, 1996–2016. Clin Infect Dis 2020; 71:1616–23.
- Nijhawan AE, Kitchell E, Etherton SS, Duarte P, Halm EA, Jain MK. Half of 30-day hospital readmissions among HIV-infected patients are potentially preventable. AIDS Patient Care STDS 2015; 29:465–73.
- Gibson MP, Nijhawan AE, Jain MK, Halm E. Thirty-day readmissions among HIV-infected individuals at a safety-net hospital: predictors and preventability. Open Forum Infect Dis 2016; 3(suppl 1):1340.
- Hoffmann CJ, Shearer K, Kekana B, et al. Reducing HIV-associated post-hospital mortality through home-based care in South Africa: a randomized controlled trial. Clin Infect Dis 2024; 78:1256–63.
- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924–6.
- Hernan MA, Hernandez-Diaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med 2013; 159:560–2.

- Guzman Ramos MI, Manzano Garcia M, Robustillo-Cortes MA, Gutierrez Pizarraya A, Morillo-Verdugo R. Influence of CMO pharmaceutical care modelbased intervention on readmission rate in high risk HIV patients: the INFARDAR study. Rev Esp Quimioter 2021; 34:459–67.
- Peck RN, Issarow B, Kisigo GA, et al. Linkage case management and posthospitalization outcomes in people with HIV: the Daraja randomized clinical trial. JAMA 2024; 331:1025–34.
- Giordano TP, Cully J, Amico KR, et al. A randomized trial to test a peer mentor intervention to improve outcomes in persons hospitalized with HIV infection. Clin Infect Dis 2016; 63:678–86.
- Eaton AD, Chan Carusone S, Craig SL, et al. The ART of conversation: feasibility and acceptability of a pilot peer intervention to help transition complex HIV-positive people from hospital to community. BMJ Open 2019; 9:e026674.
- Khawcharoenporn T, Damronglerd P, Chunloy K, Sha BE. Enhanced inpatient rounds, appointment reminders, and patient education improved HIV care engagement following hospital discharge. Int J STD AIDS 2018; 29:641–9.
- Brizzi MB, Burgos RM, Chiampas TD, et al. Impact of pharmacist-driven antiretroviral stewardship and transitions of care interventions on persons with human immunodeficiency virus. Open Forum Infect Dis 2020; 7:ofaa073.
- Nijhawan AE, Zhang S, Chansard M, Gao A, Jain MK, Halm EA. A multicomponent intervention to reduce readmissions among people with HIV. J Acquir Immune Defic Syndr 2022; 90:161–9.
- Hill L, Thompson C, Balcombe S, et al. Effects of a hospital discharge clinic among people with HIV: lack of early follow-up is associated with 30-day hospital readmission and decreased retention in care. HIV Med 2024; 25:332–42.
- Claassen CW, Bwalya C, Mujansi M, et al. Novel post-hospitalization care model to decrease mortality among people living with HIV in Zambia: pilot study. Presented at: Conference on Retroviruses and Opportunistic Infections 2024; 3–6 March 2024; Denver, CO. Abstract 1184.
- Burke RM, Twabi HH, Johnston C, et al. Interventions to reduce deaths in people living with HIV admitted to hospital in low- and middle-income countries: a systematic review. PLOS Glob Public Health 2023; 3:e0001557.
- Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service program. N Engl J Med 2009; 360:1418–28.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6: rating the quality of evidence—imprecision. J Clin Epidemiol 2011; 64:1283–93.
- Knappett M, Nguyen V, Chaudhry M, et al. Pediatric post-discharge mortality in resource-poor countries: a systematic review and meta-analysis. EClinicalMedicine 2024; 67:102380.
- Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53:1119–29.
- 29. Li Y, Fu MR, Fang J, Zheng H, Luo B. The effectiveness of transitional care interventions for adult people with heart failure on patient-centered health outcomes: a systematic review and meta-analysis including dose-response relationship. Int J Nurs Stud 2021; 117:103902.
- Ridwan ES, Hadi H, Wu YL, Tsai PS. Effects of transitional care on hospital readmission and mortality rate in subjects with COPD: a systematic review and metaanalysis. Respir Care 2019; 64:1146–56.
- Soh YY, Zhang H, Toh JJY, Li X, Wu XV. The effectiveness of tele-transitions of care interventions in high-risk older adults: a systematic review and metaanalysis. Int J Nurs Stud 2023; 139:104428.